Established in 1980, Egyptian International Pharmaceutical Industries Company (EIPICO) produced 309.6 million units in 2024, registered 13 new pharmaceutical products, and launched 10 new medications in the Egyptian market. It also completed 95% of the EIPICO 3 factory, which will produce biosimilars and their preparations, at an investment of nearly $110 million. In December 2024, Arab API, a newly established joint venture by EIPICO, ACDIMA, and the Suez Canal Economic Zone Company for Investment, signed a contract to establish a pharmaceutical industrial zone with investments of $120 million. The Arab Company for Drug Industries & Medical Appliances owned a 50% stake in EIPECO as of March 2025.